Clinical Trial Update: Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet [Phase 2]

View source ↗

Summary

Phase 2 trial in early relapsed, lenalidomide-refractory multiple myeloma evaluated a carfilzomib-based triplet regimen; results have been posted after study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-08